{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T19:01:24Z","timestamp":1751223684983},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,10,15]],"date-time":"2011-10-15T00:00:00Z","timestamp":1318636800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00345-011-0778-9","type":"journal-article","created":{"date-parts":[[2011,10,14]],"date-time":"2011-10-14T16:07:47Z","timestamp":1318608467000},"page":"451-456","source":"Crossref","is-referenced-by-count":2,"title":["Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults"],"prefix":"10.1007","volume":"30","author":[{"given":"Douglas G.","family":"Tincello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,15]]},"reference":[{"key":"778_CR1","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/j.1464-410x.2004.04806.x","volume":"93","author":"DA Turner","year":"2004","unstructured":"Turner DA, Shaw C, McGrother CW et al (2004) The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK. BJU Int 93:1246\u20131252","journal-title":"BJU Int"},{"key":"778_CR2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1464-410X.2008.08036.x","volume":"103","author":"DE Irwin","year":"2009","unstructured":"Irwin DE, Mungapen L, Milsom I et al (2009) The economic impact of overactive bladder syndrome in six Western countries. BJU Int 103:202\u2013209","journal-title":"BJU Int"},{"key":"778_CR3","first-page":"S90","volume":"15","author":"E Onukwugha","year":"2009","unstructured":"Onukwugha E, Zuckerman IH, McNally D et al (2009) The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care 15:S90\u2013S97","journal-title":"Am J Manag Care"},{"key":"778_CR4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.urology.2008.12.077","volume":"74","author":"H Kannan","year":"2009","unstructured":"Kannan H, Radican L, Turpin RS et al (2009) Burden of illness associated with lower urinary tract symptoms including overactive bladder\/urinary incontinence. Urology 74:34\u201338","journal-title":"Urology"},{"key":"778_CR5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167\u2013178","journal-title":"Neurourol Urodyn"},{"key":"778_CR6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1001\/jama.280.23.1995","volume":"280","author":"KL Burgio","year":"1998","unstructured":"Burgio KL, Locher JL, Goode PS et al (1998) Behavioral versus drug treatment for urge urinary incontinence in older women. JAMA 280:1995\u20132000","journal-title":"JAMA"},{"key":"778_CR7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF02550355","volume":"19","author":"Z Kirkali","year":"1987","unstructured":"Kirkali Z, Whitaker RH (1987) The use of oxybutynin in urological practice. Int Urol Nephrol 19:385\u2013391","journal-title":"Int Urol Nephrol"},{"key":"778_CR8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","volume":"81","author":"P Abrams","year":"1999","unstructured":"Abrams P, Freeman RM, Anderstrom C et al (1999) Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81:801\u2013810","journal-title":"Br J Urol"},{"key":"778_CR9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","volume":"93","author":"CR Chapple","year":"2004","unstructured":"Chapple CR, Rechberger T, Al-Shukri S et al (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303\u2013310","journal-title":"BJU Int"},{"key":"778_CR10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.326.7394.841","volume":"326","author":"P Herbison","year":"2003","unstructured":"Herbison P, Hay-Smith J, Ellis G et al (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 326:841\u2013844","journal-title":"BMJ"},{"key":"778_CR11","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1471-0528.1997.tb12054.x","volume":"104","author":"CJ Kelleher","year":"1997","unstructured":"Kelleher CJ, Cardozo LD, Khullar V et al (1997) A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988\u2013993","journal-title":"Br J Obstet Gynaecol"},{"key":"778_CR12","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199104253241707","volume":"324","author":"J Jankovic","year":"1991","unstructured":"Jankovic J, Brin MF (1991) Therapeutic uses of botulinum toxin. New Eng J Med 324:1186\u20131194","journal-title":"New Eng J Med"},{"issue":"1","key":"778_CR13","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1046\/j.1526-4610.43.7s.4.x","volume":"43","author":"O Dolly","year":"2003","unstructured":"Dolly O (2003) Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 43(1):S16\u2013S24","journal-title":"Headache"},{"key":"778_CR14","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","volume":"49","author":"A Apostolidis","year":"2006","unstructured":"Apostolidis A, Dasgupta P, Fowler CJ (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:644\u2013650","journal-title":"Eur Urol"},{"key":"778_CR15","doi-asserted-by":"crossref","unstructured":"Mangera A, Andersson KE, Apostolidis A et al (2011) Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA). Eur Urol doi: 10.1016\/j.eururo.2011.07.001","DOI":"10.1016\/j.eururo.2011.07.001"},{"key":"778_CR16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1464-410X.2009.08466.x","volume":"104","author":"J Grosse","year":"2009","unstructured":"Grosse J, Kramer G, Jakse G (2009) Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study. BJU Int 104:651\u2013656","journal-title":"BJU Int"},{"key":"778_CR17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","volume":"164","author":"B Schurch","year":"2000","unstructured":"Schurch B, St\u00f6hrer M, Kramer G et al (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692\u2013697","journal-title":"J Urol"},{"key":"778_CR18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","volume":"174","author":"B Schurch","year":"2005","unstructured":"Schurch B, de Seze M, Denys P et al (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196\u2013200","journal-title":"J Urol"},{"key":"778_CR19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","volume":"45","author":"A Reitz","year":"2004","unstructured":"Reitz A, St\u00f6hrer M, Kramer G et al (2004) European Experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510\u2013515","journal-title":"Eur Urol"},{"key":"778_CR20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.eururo.2004.11.009","volume":"47","author":"J Grosse","year":"2005","unstructured":"Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653\u2013659","journal-title":"Eur Urol"},{"key":"778_CR21","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/01.ju.0000169480.43557.31","volume":"174","author":"R Popat","year":"2005","unstructured":"Popat R, Aspostolidis A, Kalsi V et al (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174:984\u2013989","journal-title":"J Urol"},{"key":"778_CR22","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.urology.2004.01.041","volume":"63","author":"DE Rapp","year":"2004","unstructured":"Rapp DE, Lucioni A, Katz EE et al (2004) Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 63:1071\u20131075","journal-title":"Urology"},{"key":"778_CR23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.urology.2005.01.036","volume":"66","author":"H Schulte-Baukloh","year":"2005","unstructured":"Schulte-Baukloh H, Weiss C, Stolze T et al (2005) Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patients satisfaction. Urology 66:82\u201387","journal-title":"Urology"},{"key":"778_CR24","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","volume":"184","author":"R Dmochowski","year":"2010","unstructured":"Dmochowski R, Chapple C, Nitti VW et al (2010) Efficacy and safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial. J Urol 184:2416\u20132422","journal-title":"J Urol"},{"key":"778_CR25","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","volume":"177","author":"A Sahai","year":"2007","unstructured":"Sahai A, Khan MS, Dasgupta P (2007) Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 177:2231\u20132236","journal-title":"J Urol"},{"key":"778_CR26","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","volume":"181","author":"MK Flynn","year":"2009","unstructured":"Flynn MK, Amundsen CL, Perevich M et al (2009) Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 181:2608\u20132615","journal-title":"J Urol"},{"key":"778_CR27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","volume":"180","author":"L Brubaker","year":"2008","unstructured":"Brubaker L, Richter HE, Visco A et al (2008) Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180:217\u2013222","journal-title":"J Urol"},{"key":"778_CR28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1067\/mob.2003.379","volume":"189","author":"I Yalcin","year":"2003","unstructured":"Yalcin I, Bump RC (2003) Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 189:98\u2013101","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"778_CR29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1569-9056(11)60571-X","volume":"10","author":"DG Tincello","year":"2011","unstructured":"Tincello DG, Slack MC, Kenyon S et al (2011) Botulinum toxin-A for refractory detrusor overactivity in women: a 240 patient randomised placebo controlled trial. Eur Urol 10(2):191","journal-title":"Eur Urol"},{"key":"778_CR30","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2007.07.009","volume":"52","author":"C Chapple","year":"2007","unstructured":"Chapple C, Van KP, Tubaro A et al (2007) Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 52:1204\u20131212","journal-title":"Eur Urol"},{"key":"778_CR31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","volume":"48","author":"CR Chapple","year":"2005","unstructured":"Chapple CR, Martinez-Garcia R, Selvaggi L et al (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464\u2013470","journal-title":"Eur Urol"},{"key":"778_CR32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.sc.3101318","volume":"40","author":"JJ Wyndaele","year":"2002","unstructured":"Wyndaele JJ, van Dromme SA (2002) Muscular weakness as side effect of botulinum toxin injection of neurogenic detrusor overactivity. Spinal Cord 40:599\u2013600","journal-title":"Spinal Cord"},{"key":"778_CR33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.sc.3101736","volume":"43","author":"K Laet De","year":"2005","unstructured":"De Laet K, Wyndaele JJ (2005) Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 43:397\u2013399","journal-title":"Spinal Cord"},{"key":"778_CR34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000316080","volume":"86","author":"RM Bauer","year":"2011","unstructured":"Bauer RM, Gratzke C, Roosen A et al (2011) Patient-reported side effects of intradetrusor botulinum toxin type a for idiopathic overactive bladder syndrome. Urol Int 86:68\u201372","journal-title":"Urol Int"},{"key":"778_CR35","doi-asserted-by":"crossref","unstructured":"Duthie JB, Herbison GP, Wilson DI et al (2009) Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev (3):CD00549. doi: 10.1002\/14651858.CD005493.pub2","DOI":"10.1002\/14651858.CD005493.pub2"},{"key":"778_CR36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.juro.2010.02.009","volume":"183","author":"JT Anger","year":"2010","unstructured":"Anger JT, Weinberg A, Suttorp MJ et al (2010) Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol 183:228\u20132264","journal-title":"J Urol"},{"key":"778_CR37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","volume":"55","author":"A Apostolidis","year":"2009","unstructured":"Apostolidis A, Dasgupta P, Denys P et al (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European Consensus Report. Eur Urol 55:100\u2013120","journal-title":"Eur Urol"},{"key":"778_CR38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/nau.20611","volume":"28","author":"BL Cohen","year":"2009","unstructured":"Cohen BL, Barboglio P, Rodriguez D et al (2009) Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 28:205\u2013208","journal-title":"Neurourol Urodyn"},{"key":"778_CR39","doi-asserted-by":"crossref","unstructured":"Coelho AC, Cruz F, Cruz CD et al (2011) Spread of Onabotulinum A after injection in the bladder wall. Experimental study in guinea-pig urinary bladder using the distribution of cleaved SNAP-25. Eur Urol 10(2):189","DOI":"10.1016\/S1569-9056(11)60565-4"},{"key":"778_CR40","doi-asserted-by":"crossref","unstructured":"Cohen BL, Caruso DJ, Kanagarajah P et al (2009) Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder. Adv Urol doi: 10.1155\/2009\/328364","DOI":"10.1155\/2009\/328364"},{"key":"778_CR41","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2005.11.006","volume":"49","author":"V Kalsi","year":"2006","unstructured":"Kalsi V, Popat RB, Apostolidis A et al (2006) Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 49:519\u2013527","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-011-0778-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-011-0778-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-011-0778-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:40:00Z","timestamp":1559050800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-011-0778-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,15]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1007\/s00345-011-0778-9","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,15]]}}}